Detalles de la búsqueda
1.
14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia.
Blood
; 138(9): 773-784, 2021 09 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33876209
2.
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment.
Hematol Oncol
; 40(4): 734-742, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35618655
3.
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents.
Eur J Haematol
; 108(6): 449-459, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35156731
4.
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma.
Am J Hematol
; 97(12): 1607-1615, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36198076
5.
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia.
Eur J Haematol
; 105(1): 47-55, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32145118
6.
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery.
Cancer
; 125(5): 712-725, 2019 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30480765
7.
Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells.
Haematologica
; 102(7): 1204-1214, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28411256
8.
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities.
Genes Chromosomes Cancer
; 55(4): 375-88, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26815134
9.
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant.
Hematol Oncol
; 39(4): 580-583, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-33963566
10.
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia.
Blood
; 121(26): 5138-44, 2013 Jun 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-23678005
11.
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.
Am J Hematol
; 90(6): 515-23, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25753065
12.
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.
Blood
; 120(4): 761-7, 2012 Jul 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-22692507
13.
FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities.
BMC Cancer
; 14: 396, 2014 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-24893616
14.
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features.
Nat Commun
; 15(1): 1551, 2024 Feb 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38378709
15.
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party.
Blood
; 117(21): 5591-9, 2011 May 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-21450900
16.
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis.
Blood
; 117(25): 6793-800, 2011 Jun 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-21447834
17.
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation.
Ann Hematol
; 92(9): 1271-80, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23660628
18.
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights.
Cells
; 12(13)2023 06 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-37443737
19.
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study.
Cancer Med
; 12(10): 11838-11848, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36999931
20.
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS.
Proc Natl Acad Sci U S A
; 106(39): 16811-6, 2009 Sep 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-19805378